18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 540 KiB)
Rivas, A.; Delyon, J.; Martineau, A.; Blanc, E.; Allayous, C.; Da Meda, L.; Merlet, P.; Lebbé, C.; Baroudjian, B.; Vercellino, L. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers 2022, 14, 3190. https://doi.org/10.3390/cancers14133190
Rivas A, Delyon J, Martineau A, Blanc E, Allayous C, Da Meda L, Merlet P, Lebbé C, Baroudjian B, Vercellino L. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers. 2022; 14(13):3190. https://doi.org/10.3390/cancers14133190
Chicago/Turabian StyleRivas, Alexia, Julie Delyon, Antoine Martineau, Estelle Blanc, Clara Allayous, Laetitia Da Meda, Pascal Merlet, Céleste Lebbé, Barouyr Baroudjian, and Laetitia Vercellino. 2022. "18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors" Cancers 14, no. 13: 3190. https://doi.org/10.3390/cancers14133190